6-(5,6-Dihydroxy-4-oxo-2-phenylchromen-7-yl)oxy-3,4,5-trihydroxyoxane-2-carboxylic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: 6-(5,6-Dihydroxy-4-oxo-2-phenylchromen-7-yl)oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
• 化学式: C₂₁H₁₈O₁₁
• mdl: MFCD00571874
• 分子量: 446.4
• InChiKey: IKIIZLYTISPENI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  183
• 氢给体数：
  6
• 氢受体数：
  11

文献信息

• Process for synthesis of Oroxylin A
  申请人：Majeed Muhammed

  公开号：US10407401B1

  公开（公告）日：2019-09-10

  Disclosed is a novel, simple, scalable and environment friendly process for the synthesis of Oroxylin A from Baicalin. Baicalin is esterified to obtain a methyl ester which is further selectively methylated to provide Oroxylin A glucuronide methyl ester which on de-glycosylation results in the formation of Oroxylin A.

  揭示了一种新颖、简单、可扩展且环境友好的过程，用于从黄芩苷合成黄芩素A。将黄芩苷酯化以获得甲酯，进一步选择性地进行甲基化以提供甲酯化的黄芩素A葡萄糖苷，脱糖后形成黄芩素A。
• CYCLIN-DEPENDENT PROTEIN KINASES INHIBITORS OF SCUTELLARIA FLAVONOID ORGANIC AMINE DERIVATIVES, SYNTHESIS AND USE THEREOF
  申请人：Zhang Shixuan

  公开号：US20100197619A1

  公开（公告）日：2010-08-05

  The present invention provides a series of cyclin-dependent protein kinases (Cdks) inhibitors, Scutellaria flavonoid organic amine derivatives, synthesis and use thereof. The preparation method is as follows: taking Baicalein (or Wogonin) from Scutellaria baicalensis as lead compound, mixting it with formaldehyde solution and organic amine compounds based on the molar ratio of 1:1-1.2:1-1.2, adding methanol of duplicate weight than baicalein and reacting at 50-70° C., filtering the sediment and washing and then drying so as to get the product with a content of not less than 97% (weight). Similar to Flavopiridol and P276-00, the activity of baicalein organic amine derivatives inhibiting Cdks has an increase of 50 times compared with that of Baicalin. It can selectively induce apoptosis of the proliferative phase cancer cells, which has scarcely any influence to the normal structure, and it belongs to anticancer drugs of cell cycle inhibitor kind. The product has a rich source of raw materials and has simple process, high purity, low cost, clear metabolic mechanism, high efficiency and low toxicity, which can be made into oral preparations or injections together with acid salts and is expected to become high efficient and low toxicity anti-cancer and AIDS drugs.

  本发明提供了一系列依赖于细胞周期蛋白激酶（Cdks）的抑制剂，即黄芩黄酮有机胺衍生物，其合成和使用方法。制备方法如下：以黄芩中的黄芩素（或黄芩苷）为引物化合物，与甲醛溶液和有机胺化合物按摩尔比1:1-1.2:1-1.2混合，加入重量为黄芩素两倍的甲醇，在50-70°C下反应，过滤沉淀并洗涤，然后干燥以得到含量不低于97%（重量）的产品。类似于Flavopiridol和P276-00，黄芩素有机胺衍生物抑制Cdks的活性比黄芩苷增加了50倍。它可以选择性地诱导增殖期癌细胞的凋亡，对正常结构几乎没有影响，属于细胞周期抑制剂类的抗癌药物。该产品具有丰富的原材料来源和简单的工艺，高纯度，低成本，代谢机制清晰，效率高，毒性低，可以与酸盐一起制成口服制剂或注射剂，预计将成为高效低毒的抗癌和艾滋病药物。
• [EN] BIO-RELATED SUBSTANCE MODIFIED BY MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE<br/>[FR] SUBSTANCE D'ORIGINE BIOLOGIQUE MODIFIÉE PAR UN DÉRIVÉ DU POLYÉTHYLÈNEGLYCOL MULTIFONCTIONNALISÉ<br/>[ZH] 一种多官能化聚乙二醇衍生物修饰的生物相关物质
  申请人：XIAMEN SINOPEG BIOTECH CO LTD

  公开号：WO2016050208A1

  公开（公告）日：2016-04-07

  本发明公开一种多官能化聚乙二醇衍生物（式1）修饰的生物相关物质。其具有H型结构，包括一个线性主轴LPEG及四个PEG分支链，n1、n2、n3、n4分别为分支链的聚合度；U1、U2为连接LPEG和两个PEG分支链的三价支化基团；F1、F2含有功能性基团或其被保护形式R01，且R01的个数为1个或多个。分子中任一个连接基或其与相邻杂原子基团形成的连接基可稳定存在或可降解；分子中任一个PEG链段各自独立地为多分散性或单分散性。1个H型分子可修饰多种或多个生物相关物质，修饰产物支化结构灵活，具有高载药量、可优化的药代动力学和组织分布情况，还可携带2种不同功能的生物相关物质，产生荧光性质或靶向功能。
• STANDARDIZED EXTRACTS OF SCUTELLARIA LATERIFLORA
  申请人：Phytos, Inc.

  公开号：EP1446135B1

  公开（公告）日：2007-07-25
• Methods of Treating Muscular Dystrophies
  申请人：Squadrito Francesco

  公开号：US20100190733A1

  公开（公告）日：2010-07-29

  The invention relates to methods of treating Duchenne muscular dystrophy with flavonoids. The methods may include (a) providing a pharmaceutical composition comprising a therapeutically effective amount of flavonoid, and (b) administering the composition to a human patient, wherein the flavonoid comprises an isoflav-4-one with at least one of the carbons located at positions 8, 7, 6, 5, 2, 2′, 3′, 4′, 5′, or 6′ modified by an alcohol group. Alternatively, the flavonoid may comprise (1) a flavan-3-ol with at least one of the carbons located at positions 8, 7, 6, 5, 4, 2′, 3′, 4′, 5′, or 6′ modified by an alcohol group, or (2) a Free-B-Ring flavone with at least one of the carbons located at positions 8, 7, 6, 5 or 3 modified by an alcohol group and with at least one of the carbons located at positions 8, 7, 6, 5 or 3 modified by a glycoside group.